151. Postoperative chemotherapy is associated with prognosis of stage IV colorectal cancer treated with preoperative chemotherapy/chemoradiotherapy and curative resection
- Author
-
Yasutaka Shuno, Manabu Kaneko, Soichiro Ishihara, Hirofumi Sonoda, Koji Murono, Kazushige Kawai, Toshiaki Tanaka, Takeshi Nishikawa, Keisuke Hata, Hiroaki Ishii, Shigenobu Emoto, Kazuhito Sasaki, and Hiroaki Nozawa
- Subjects
Curative resection ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Preoperative chemotherapy ,Humans ,Neoplasm Staging ,Postoperative Care ,Chemotherapy ,Postoperative chemotherapy ,business.industry ,Chemoradiotherapy ,Hepatology ,medicine.disease ,Prognosis ,Survival Analysis ,030220 oncology & carcinogenesis ,Multivariate Analysis ,030211 gastroenterology & hepatology ,business ,Stage iv ,Colorectal Neoplasms ,Follow-Up Studies - Abstract
Advances in systemic chemotherapy have increased the resectability in colorectal cancer (CRC) associated with metastases even if it was initially unresectable. However, what determines the prognosis of stage IV CRC patients treated by preoperative therapy and surgery remains unclear. We attempted to identify prognostic factors in such CRC patients. We reviewed stage IV CRC patients who underwent curative resection between December 2007 and May 2019. The patients who underwent conversion chemotherapy for initially unresectable disease and those who received neoadjuvant chemotherapy (NAC) for resectable synchronous metastases or neoadjuvant chemoradiotherapy (NACRT) for advanced lower rectal cancer with resectable metastases were included. Recurrence-free survival (RFS) and overall survival (OS) were examined by multivariate analyses using Cox proportional hazard models. The RFS and OS curves were analyzed according to postoperative adjuvant chemotherapy (AC). Among 70 patients who underwent curative surgery (34 men, mean age: 60 years old), 33 had initially unresectable disease, 23 received NAC, and 14 NACRT. By multivariate analyses, AC was an independent predictor for improved RFS and OS (hazard ratio = 0.29, p = 0.0002, and hazard ratio = 0.37, p = 0.025). Patients treated with AC showed improved RFS and OS than those without AC (2-year RFS rate = 30% vs 19%, p = 0.031, and 3-year OS rate = 87% vs 67%, p = 0.045). Because of its association with improved prognosis, AC should be considered for stage IV CRC patients after curative resection regardless of initial resectability status and preoperative therapy.
- Published
- 2019